G. Hechmati

发表

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries

J. Body, D. Bhowmik, R. V. Von Moos, 2017, Journal of bone oncology.

Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study.

V. Lorusso, I. Durán, D. Lüftner, 2014, Molecular and clinical oncology.

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

M. Peeters, V. Gastañaga, Aliki Taylor, 2015, European journal of cancer.

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

J. Tabernero, J. Canon, G. Bodoky, 2016, ESMO Open.

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

A. Stopeck, A. Brufsky, D. Bhowmik, 2020, Journal of medical economics.

Health resource utilisation associated with skeletal‐related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study

H. Ghazal, I. Durán, D. Lüftner, 2017, European journal of cancer care.

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States

J. Body, D. Henry, D. Bhowmik, 2019, Current medical research and opinion.

Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study

V. Lorusso, I. Durán, D. Lüftner, 2013, Journal of medical economics.

Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries

J. Body, E. Terpos, N. Maniadakis, 2016, Journal of bone oncology.

Health resource utilization associated with skeletal-related events: results from a retrospective European study

H. Nahi, J. Body, E. Terpos, 2015, The European Journal of Health Economics.

Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study

V. Lorusso, I. Durán, D. Lüftner, 2014, SpringerPlus.

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study

J. Body, E. Terpos, N. Maniadakis, 2018, Journal of bone oncology.

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

A. Caraceni, V. Adamo, P. Pedrazzoli, 2017, Supportive Care in Cancer.

Cost of skeletal complications from bone metastases in six European countries

J. Body, E. Terpos, N. Maniadakis, 2016, Journal of medical economics.

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe

J. Body, D. Bhowmik, A. Rider, 2018, Journal of bone oncology.

The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone.

J. Douillard, B. Barber, A. Rong, 2015 .

Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective

T. Delea, J. Franklin, G. Hechmati, 2017, Journal of medical economics.

Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

B. Barber, C. Graham, G. Hechmati, 2014, European journal of cancer.

Physicians' preferences for bone metastases drug therapy in the United States.

A. Hauber, H. Collins, F. Gatta, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective – prospective observational study – a cohort from 4 European countries

V. Lorusso, I. Durán, D. Lüftner, 2014, Journal of bone oncology.

771 Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases

J. Body, D. Bhowmik, A. Rider, 2016 .

International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC).

A. Liede, G. Hechmati, J. Arellano, 2013 .

Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

M. Fakih, B. Barber, C. Graham, 2015, Journal of medical economics.

Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom

A. Hauber, J. Body, A. Bahl, 2013, BMC Health Services Research.

Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study

V. Lorusso, I. Durán, D. Lüftner, 2014, Journal of clinical medicine.

Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer

J. Douillard, B. Barber, Jianmin Wang, 2016, Current medical research and opinion.

A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US

C. Graham, J. Strickler, G. Hechmati, 2018, Journal of medical economics.

Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom

Yi Qian, A. Brett Hauber, Ateesha F. Mohamed, 2014, Supportive Care in Cancer.

The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium

J. Body, P. Chevalier, M. Lamotte, 2013, Journal of medical economics.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

M. Intorcia, N. Raje, G. Roodman, 2018, Journal of medical economics.

Healthcare resource use and costs associated with renal impairment in US patients with bone metastases from solid tumors

David M. Smith, E. Thomson, D. Bhowmik, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors

A. Hauber, F. Gatta, G. Hechmati, 2016, The Patient - Patient-Centered Outcomes Research.

Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.

M. Fakih, T. Price, B. Barber, 2016, Clinical therapeutics.

Cost-effectiveness analysis of panitumumab plus mFOLFOX 6 compared with bevacizumab plus mFOLFOX 6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

B. Barber, C. Graham, G. Hechmati, 2014 .

PCN115 Cost of Skeletal-Related Events (SREs) in Patients with Bone Metastases to solid Tumours Based on the Health Resource Utilisation (HRU) Collected in a Prospective European Multinational Observational Study

I. Durán, D. Lüftner, A. Bahl, 2011 .

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials

S. Siena, F. Gatta, G. Hechmati, 2016, Quality of Life Research.

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

M. Peeters, V. Gastañaga, Aliki Taylor, 2015, European journal of cancer.

Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.

G. de Pouvourville, B. Barber, C. Graham, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.